NEXT GENERATION SEQUENCING AND CYTOGENETICS IN ACUTE MYELOID LEUKEMIA - THERAPEUTIC AND PROGNOSTIC IMPACT: A RETROSPECTIVE COHORT FROM A PRIVATE CENTRE OF REFERENCE IN LATIN AMERICA

Autor: FGB Chaves, JD Rocha, LJ Arcuri, PV Campregher, FPS Santos, JZMD Nascimento, TS Datoguia, AID Ennes, EC Chapchap, N Hamerschlak

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S240-S241 (2023)

Introduction: Acute Myeloid Leukemia (AML) is a prevalent and severe hematological disorder. Emergence of Next-Generation Sequencing (NGS) and karyotiping, has demonstrated associations between chromosomal abnormalities and mutations with worse treat

Externí odkaz: https://doaj.org/article/aab40beeb0aa486fb9ee1e12ea4a030e

IMUNOFENOTIPAGEM E ANÁLISE MOLECULAR NO DIAGNÓSTICO DE LEUCEMIA AGUDA DE FENÓTIPO MISTO: RELATO DE CASO

Autor: LFBH Junior, RS Kojima, ACLD Nascimento, AID Ennes, JZMD Nascimento, JD Rocha, EC Chapchap, FPS Santos, TS Datoguia, N Hamerschlak

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S305-S306 (2023)

Introdução: A leucemia aguda de fenótipo misto (MPAL) representa 1 a 5% dos casos de leucemia e se refere à uma leucemia com expressão de duas linhagens simultaneamente, sejam elas B, T, ou mieloide. Essa entidade rara tem difícil diagnóstico

Externí odkaz: https://doaj.org/article/ef250391d1314eb184120d53d87c69a7

APLICAÇÃO DO SCORE PROGNÓSTICO DIPSS-PLUS EM PACIENTES PORTADORES DE MIELOFIBROSE PRIMÁRIA E SECUNDÁRIA DE DUAS INSTITUIÇÕES PRIVADAS BRASILEIRAS

Autor: R Centrone, LFS Dias, LC Travassos, TS Datoguia, M Bellesso, A Alves, N Hamerschlak, R Santucci, FPS Santos

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S126- (2021)

Introdução: Mielofibrose é uma rara neoplasia mieloproliferativa crônica de apresentação clínica e prognóstico extremamente heterogêneos. A aplicação de scores prognósticos têm demonstrado grande impacto nas decisões e respostas terapê

Externí odkaz: https://doaj.org/article/db4e9ddc3669469dbf1469681c7cb0e1

LEUCEMIA MIELÓIDE AGUDA – CENÁRIO DA DOENÇA NA ÚLTIMA DÉCADA NO HOSPITAL ISRAELITA ALBERT EINSTEIN

Autor: CLM Pereira, LFS Dias, NF Centurião, R Helman, IE Lopes, TS Datoguia, PV Campregher, GF Perini, N Hamerschlak, FPS Santos

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S164-S165 (2021)

Introdução: Leucemia Mielóide Aguda (LMA) é a leucemia aguda mais comum em adultos, classificada pela Organização Mundial de Saúde em LMA com anormalidades genéticas recorrentes (AGR), com alterações relacionadas à mielodisplasia (SMD), re

Externí odkaz: https://doaj.org/article/56a16e4776af4e68bc5fe365e7680900

An Extended Flow Cytometry Evaluation of ex Vivo Expanded NK Cells Using K562.Clone1, a Feeder Cell Line Manufactured in Brazil.

Autor: Watanabe CM; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil., Suzuki CI; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil., Dos Santos AM; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil., Aloia TPA; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil., Lee G; Department of Pathology, Case Western Reserve University, Cleveland, Ohio., Wald D; Department of Pathology, Case Western Reserve University, Cleveland, Ohio; Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio., Okamoto OK; Department of Hemotherapy and Cellular Therapy, Hospital Israelita Albert Einstein, São Paulo, Brazil; Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo, São Paulo, Brazil., de Azevedo JTC; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil; Department of Hemotherapy and Cellular Therapy, Hospital Israelita Albert Einstein, São Paulo, Brazil., de Godoy JAP; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil; Department of Hemotherapy and Cellular Therapy, Hospital Israelita Albert Einstein, São Paulo, Brazil., Santos FPS; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil; Oncology and Hematology Center, Familia Dayan-Daycoval, Hospital Israelita Albert Einstein, São Paulo, Brazil., Weinlich R; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil., Kerbauy LN; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil; Department of Hemotherapy and Cellular Therapy, Hospital Israelita Albert Einstein, São Paulo, Brazil; Oncology and Hematology Center, Familia Dayan-Daycoval, Hospital Israelita Albert Einstein, São Paulo, Brazil., Kutner JM; Department of Hemotherapy and Cellular Therapy, Hospital Israelita Albert Einstein, São Paulo, Brazil; Oncology and Hematology Center, Familia Dayan-Daycoval, Hospital Israelita Albert Einstein, São Paulo, Brazil., Paiva RMA; Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil; Department of Hemotherapy and Cellular Therapy, Hospital Israelita Albert Einstein, São Paulo, Brazil. Electronic address: raquel.paiva@einstein.br., Hamerschlak N; Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo, São Paulo, Brazil.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Nov; Vol. 30 (11), pp. 1063.e1-1063.e19. Date of Electronic Publication: 2024 Jul 08.